Shanghai Henlius Biotech
Clinical trials sponsored by Shanghai Henlius Biotech, explained in plain language.
Shanghai Henlius Biotech is a biopharmaceutical company developing biosimilars and innovative drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cancer drug HLX42 enters first human trial Results expected Sep 2026 (estimated)
- New combo therapy shows promise for aggressive lung cancer in japanese patients Results expected Oct 2026 (estimated)
- New drug combo aims to shrink Hard-to-Treat tumors Results expected Oct 2026 (estimated)
- New drug HLX43 targets tough esophageal cancers Results expected Oct 2026 (estimated)
- New hope for Hard-to-Treat nasopharyngeal cancer: targeted drug HLX43 enters phase 2 trial Results expected Nov 2026 (estimated)
-
New immunotherapy combo shows promise for tough lung cancer
Disease control CompletedThis Phase 3 trial tested whether adding an experimental immunotherapy drug called HLX10 to standard chemotherapy could help people with extensive-stage small cell lung cancer live longer. The study enrolled 585 people who had not received prior treatment. Participants were rando…
Phase 3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New antibody for lung scarring passes first safety check in healthy volunteers
Disease control CompletedThis study tested a single dose of HLX6018, an experimental antibody, in 66 healthy adults to see if it is safe and how the body handles it. HLX6018 is designed to block a protein pathway involved in idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs. Because thi…
Phase 1 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 26, 2026 18:59 UTC